Steward Partners Investment Advisory’s Axsome Therapeutics AXSM Stock Holding History

Steward Partners Investment Advisory’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.92K	Hold	35	–	–	﹤0.01%	3743
2025 Q4	$6.39K	Buy	35 +25	+250%	+$3.49K	﹤0.01%	3613
2025 Q3	$1.22K	Hold	10	–	–	﹤0.01%	4023
2025 Q2	$1.04K	Buy	10 +6	+150%	+$635	﹤0.01%	3850
2025 Q1	$467	Hold	4	–	–	﹤0.01%	3866
2024 Q4	$338	Buy	+4	New	+$368	﹤0.01%	3878
2022 Q4	–	Sell	-214	Closed	-$10K	–	3365
2022 Q3	$10K	Sell	214 -4,286	-95%	-$214K	﹤0.01%	2518
2022 Q2	$172K	Hold	4,500	–	–	﹤0.01%	1268
2022 Q1	$186K	Hold	4,500	–	–	﹤0.01%	1328
2021 Q4	$170K	Buy	4,500 +700	+18%	+$25.8K	﹤0.01%	1379
2021 Q3	$125K	Buy	3,800 +3,700	+3,700%	+$144K	﹤0.01%	1458
2021 Q2	$7K	Sell	100 -400	-80%	-$24K	﹤0.01%	6359
2021 Q1	$28.3K	Buy	+500	New	+$35.2K	﹤0.01%	2295

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Steward Partners Investment Advisory's AXSM Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 35 shares worth $5.92K. The position accounts for ﹤0.01% of the portfolio, ranked #3743.

Steward Partners Investment Advisory first reported a position in AXSM in Q1 2021 and has held it in 13 quarters since. The position peaked at $186K in Q1 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Steward Partners Investment Advisory held 35 shares of Axsome Therapeutics worth $5.92K as of Q1 2026.
Steward Partners Investment Advisory left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #3743 holding.
Steward Partners Investment Advisory first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 13 quarters since.
Steward Partners Investment Advisory's Axsome Therapeutics position peaked at $186K in Q1 2022.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.